Etonogestrel and Ethinyl Estradiol Vaginal vs Norethindrone and Ethinyl Estradiol and Ferrous — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Estrogen

Etonogestrel and Ethinyl Estradiol Vaginal

Brand: EnilloRing

First FDA approval: 2023-08-15

Estrogen

Norethindrone and Ethinyl Estradiol and Ferrous

Brand: AUROVELA Fe

First FDA approval: 2003-09-18

Lowest NADACAcquisition cost floor across all NDCs

$50.04Per unit

$0.128Per unit

Average NADACAcross all dosage forms and strengths

$50.04Up to $50.04

$0.799Up to $8.23

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only